| Name | No. | For Patients with | Purpose | |
|---|---|---|---|---|
| CA057-001 | CA057-001 | Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment. |
|
DSSG Group: Lymphoma & blood cancers
CA058-1019
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CA058-1019 | CA058-1019 | Relapsed or refractory multiple myeloma who have already had 2 to 3 lines of MM therapy, including a drug called lenalidomide and a drug from a class called anti-CD38 antibodies. |
The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM). |
MK-2140-003
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MK-2140-003 | MK2140-003 | For patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL |
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. |
MK-1026-003
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MK-1026-003 | 21-22 | Hematologic malignancies of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Richter’s transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström’s macroglobulinemia (WM) |
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Richter’s transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström’s macroglobulinemia (WM). |
BRUIN CLL-322
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| BRUIN CLL-322 | 20-21-44 | Previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma |
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years. |
MajesTEC-4
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MajesTEC-4 | 23-21 | Newly diagnosed multiple myeloma |
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant. |
EXCALIBER-RRMM
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| EXCALIBER-RRMM | 21-10 | relapsed or refractory multiple myeloma |
This study is to compare Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma |
AFFIRM-AL
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| AFFIRM-AL | 22-13 | The target population for this study are Mayo Stage IV AL amyloid patients |
This study is a Phase III, global, randomised double-blind trial of birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients |
Isa-RVD
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Isa-RVD | 19-34 | The target population for this study are patients with newly diagnosed multiple myeloma for high dose therapy and autologous stem cell transplant. Patients will have a confirmed diagnosis of multiple myeloma, based on standard IMWG criteria. |
This study is a Phase II, multi-centre, single-arm, open-label study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in patients with newly diagnosed multiple myeloma |
INDEPENDENCE ACE-536-MF-002
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| INDEPENDENCE ACE-536-MF-002 | 20-34 | Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions |
This Study is to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions. |